LXRX News and Press, Lexicon Pharmaceuticals Inc. From 04/08/21

THE WOODLANDS, Texas, April 08, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, Lexicon’s executive vice president, corporate and administrative affairs and chief financial officer, will participate in a live fireside ch...

Sotagliflozin won't die, and in the absence of a marketing partner, management is committed to pursuing FDA approval for the heart failure indication on their own. Upcoming studies of rival drugs Farxiga (DELIVER) and Jardiance (EMPEROR-Preserved) in HF patients with preserved EF will...

Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2020 Results Conference Call March 10, 2021 5:00 PM ET Company Participants Chas Schultz - Executive Director of Corporate Communications & Patient Advocacy Lonnel Coats - President and Chief Executive Officer and Director Praveen Tyle - Executive V...

Lexicon Pharmaceuticals (LXRX): Q4 GAAP EPS of -$0.04 beats by $0.25.Revenue of $0.2M (-97.7% Y/Y) beats by $0.1M.As of December 31, 2020, Lexicon had $152.3 million in cash and investments, as compared to $271.7 million as of December 31, 2019.Lexicon raised $70 million in net proceeds from ...

THE WOODLANDS, Texas, March 10, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and full-year ended December 31, 2020 and provided an update on key milestones. “During 2020, we substantially st...

THE WOODLANDS, Texas, March 04, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter and full-year 2020 financial results on Wednesday, March 10, 2021 after the markets close. Management will conduct a conference call and live webcas...

Sotagliflozin was rejected by the FDA in 2019 citing diabetic ketoacidosis in type 1 diabetes patients. This time, the company has a new approach and some strong CV benefits data that may change the FDA's viewpoint. The stock has had a marathon run in the last 3-4 months. Fo...

Investing in biotech stocks is a risky endeavor, but sometimes you can eke out a return without facing as much potential trouble as usual. By identifying companies that are likely to report rapid revenue growth in the next few years, you'll be most of the way toward profit. Of course, t...

A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions. A look back at companies I have written articles about over the last three years - 2018-2020. The good, the bad and the ugly! For further details see: Fin...

After more than doubling in value on Thursday, shares of Lexicon Pharmaceuticals (NASDAQ: LXRX) are giving up some of those gains on Friday. The company's stock was down by 13.7% as of 12:39 p.m. EST today, after dropping by as much as 18.6% earlier in the day. The company did n...